相关实验视频

Updated: Jul 23, 2025

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

对Icariside II针对膀癌的网络药理学分析

Kancheng He¹, Jinhua Wang², Yihong Zhou³

¹Department of Urology, The Fifth Affiliated Hospital of Sun Yat-sen University, No.52 Meihua Dong Road, ZhuHai, 519000, China; Department of Urology, The First People's Hospital of Foshan, Foshan, China.

European journal of pharmacology

|July 17, 2023

概括

伊卡利西德II (ICA-II) 通过阻断细胞循环,有效地抑制膀癌 (BC) 的进展,在临床前模型中显示出低毒性. 这种天然化合物在膀癌治疗中显示出治疗潜力.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
药理学药理学是指药理学的学科.
在瘤学瘤学.

背景情况:

膀癌 (BC) 由于其高复发率和进展率,对全球健康构成重大威胁.
伊卡里西德II (ICA-II) 是一种黄醇糖化物,在各种癌症中表现出抗瘤特性,但其在BC中的机制尚未研究.

研究的目的:

在膀癌 (BC) 中研究Icariside II (ICA-II) 的药理机制.
通过生物信息学和实验验证,在BC中确定ICA-II的潜在目标和信号通路.

主要方法:

生物信息学分析和分子对接以预测ICA-II目标和途径.
在体外测试 (MTT,细胞循环) 和西斑 (WB) 验证在膀癌细胞系的影响.
在现场膀癌模型评估疗效和毒性.

主要成果:

ICA-II枢纽基因与细胞周期有关,分子对接证实与CCNB1.1相互作用.
通过阻止细胞循环和降低CCNB1表达,ICA-II抑制了BC细胞的增殖.
在现场模型显示ICA-II抑制了BC生长,没有观察到肝毒性或毒性.

结论:

ICA-II通过通过细胞循环阻断抑制扩散和进展,证明了膀癌的显著治疗潜力.
ICA-II具有良好的安全性,对肝脏和脏的毒性较低.
网络药理学与实验验证相结合,支持ICA-II作为治疗膀癌的有前途药物.

关键词:

膀癌是一种癌症.伊卡里西德二号伊卡里西德二号机理机制机理机制网络药理学网络药理学

更多相关视频

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...